infigratinib,futibatinib,nivolumab,pemigatinib
helsinn,bridgebio,incyte,pfizer,otsuka,specialised therapeutics,xediton pharmaceuticals,bms,otsuka
['n/r', 'pemigatinib', 'foenix-cca2', 'infigratinib', 'futibatinib']
foenix-cca2 phase 2 trial: futibatinib for icca with fgfr2 fusion/rearrang and pd 1l orr 41.7% mdor 9.5 mo mpfs was 8.9 mo, 12mo pfs 35.4% mos 20.0 12mo os 73.1%
~ population of pemigatinib and infigratinib next? study co-alterations and mor!
#asco22
Brazilian Medical Oncologist, Advanced Fellow at GI Medical Oncology Service - MSKCC #gicancers